The effect of amantadine on the recovery of patients with traumatic brain injury

The effect of amantadine on the recovery of patients with severe brain injury: a randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190618043934N18

Enrollment

Registered

2023-07-14

Start date

2023-08-22

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain injury. Diffuse traumatic brain injury

Interventions

Intervention 1: Intervention group: The first intervention group: Group A receiving amantadine 100 mg twice a day (8:00 a.m. to 8:00 p.m.) for 6 weeks. Intervention 2: Control group: The first control

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: Age more than 16 years GCS=8 Possibility of receiving medicine through NG or OG tube Obtaining consent from the patient to enter the study after she regains consciousness and recovers(????)

Exclusion criteria

Exclusion criteria: Pregnancy Diabetes disease Dyslipidemia Cancer Congenital, ischemic and atherosclerotic heart disease Kidney failure Patients with unknown identity Kidney disease Use of dopanergic agents by the patient Contraindications for the use of amantadine

Design outcomes

Primary

Measure	Time frame
Glasgow Coma Scale. Timepoint: First and before the intervention, the third day of the intervention and the seventh day of the intervention. Method of measurement: Using the Glasgow coma criteria table and clinical examination by a neurosurgery assistant.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZabihullah Mohaqiq

Birjand University of Medical Sciences

oabstudent@gmail.com+98 56 3232 3232

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026